Eli Lilly on Thursday announced it has filed additional lawsuits against medical spas, wellness centers and other similar entities, which allegedly have been selling unapproved compounded versions of the pharma’s best-selling GLP-1 receptor agonist tirzepatide.
Gilead Sciences’ antiviral demonstrated 100% efficacy for HIV prevention in cisgender women in Phase III trial results announced Thursday.
Budd joined Peregrine Market Access in February 2024 as part of the company’s graduate intern program and has now been hired as a junior art director.
PTC Therapeutics announced Thursday that its Huntington’s disease candidate PTC518 is no longer subject to an FDA partial clinical hold after it showed positive interim results from a Phase II study.
Vaxxinity published data Thursday showing that its experimental immunotherapy could improve daily movement in Parkinson’s patients and elicit antibodies against a toxic protein involved in the disease process.
SMITM CAPITAL MARKETS LTD. has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc., entailing a capital commitment of $5 million to fuel MABT’s groundbreaking efforts to combat rabies.